Evidence map›Paper›PMID 41755019›Full record

ArticlePharmaceutics2026

Cytotoxic and Cytostatic Effects of Nanoformulated Fenretinide on MG63 Osteosarcoma Cells.

Lorenzo Anconelli, Francesca Farioli, Martina Rossi, Pietro Lodeserto, Aikaterini Andreadi, Giovanna Farruggia, Concettina Cappadone, Paolo Blasi, Isabella Orienti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lorenzo AnconelliDepartment of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19/2, 40127 Bologna, Italy.ORCID 0009-0004-3962-204X
Francesca FarioliDepartment of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19/2, 40127 Bologna, Italy.
Martina RossiDepartment of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19/2, 40127 Bologna, Italy.ORCID 0000-0002-0928-7533
Pietro LodesertoSection of Endocrinology and Metabolic Diseases, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Aikaterini AndreadiSection of Endocrinology and Metabolic Diseases, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-2294-5833
Giovanna FarruggiaDepartment of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19/2, 40127 Bologna, Italy.ORCID 0000-0003-3599-7034
Concettina CappadoneDepartment of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19/2, 40127 Bologna, Italy.ORCID 0000-0002-3874-6815
Paolo BlasiDepartment of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19/2, 40127 Bologna, Italy.ORCID 0000-0002-8543-4275
Isabella OrientiDepartment of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19/2, 40127 Bologna, Italy.ORCID 0000-0003-1972-2807

Funding

University of Bologna RFO2023
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bovine serum albumindisplacementenhanced drug solubilityhydroxypropyl-betacyclodextrininstantaneous velocityN-(4-hydroxyphenyl) retinamidetertiary complextrack speed

Identifiers

PMID41755019
PMCPMC12944098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.